{"id":648270,"date":"2023-04-20T17:14:01","date_gmt":"2023-04-20T17:14:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=648270"},"modified":"2023-04-20T17:14:01","modified_gmt":"2023-04-20T17:14:01","slug":"graftversushost-disease-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-csl-behring-medac-elsalys-biotech-kadmon-therapeutics-incyte-cor","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/graftversushost-disease-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-csl-behring-medac-elsalys-biotech-kadmon-therapeutics-incyte-cor_648270.html","title":{"rendered":"Graft-versus-host disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies &#8211; CSL Behring, Medac, ElsaLys Biotech, Kadmon Therapeutics, Incyte Cor"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1681881876.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Graft-versus-host disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies - CSL Behring, Medac, ElsaLys Biotech, Kadmon Therapeutics, Incyte Cor\" src=\"https:\/\/www.abnewswire.com\/uploads\/1681881876.jpeg\" alt=\"Graft-versus-host disease Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Companies - CSL Behring, Medac, ElsaLys Biotech, Kadmon Therapeutics, Incyte Cor\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Graft-versus-host disease Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Graft Versus Host Disease (GvHD) &#8211; Market Insights, Epidemiology, and Market Forecast\u20142032\u2019 report delivers an in-depth understanding of the GvHD, historical and forecasted epidemiology as well as the GvHD market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight has launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-market?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&#8220;Graft-versus-host disease &#8211; Market Insights, Epidemiology, and Market Forecast-2032&rdquo;.<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-market?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;Graft-versus-host disease &ndash; Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/a> report delivers an in-depth understanding of the Graft-versus-host disease, historical and forecasted epidemiology as well as the Graft-versus-host disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Graft-versus-host disease Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In 2020, the seven major countries reported 24,049 allogeneic cases, with a CAGR projecting an increased number of cases by 2032. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.<\/li>\n<li>GvHD is categorized into two types: aGvHD and cGvHD. In the 7MM, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854 in the year 2020, which is expected to rise during the forecast period.&nbsp;<\/li>\n<li>Germany has the highest number of GvHD cases by type (acute and chronic) among the EU-5 nations, with 2,984 cases in 2020.&nbsp;<\/li>\n<li>In 2020, the overall number of cGvHD cases by grading in the United Kingdom were&nbsp; 134, 209, and 159 respectively for mild, moderate, and severe cGvHD. According to the analysis, by 2032, the total number of severity-specific incident cases for the cGvHD is predicted to grow at a significant rate in the United Kingdom.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Key benefits of the report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Graft-versus-host disease market report covers a descriptive overview and comprehensive insight of the Graft-versus-host disease Epidemiology and Graft-versus-host disease&nbsp; market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Graft-versus-host disease market report provides insights on the current and emerging therapies.<\/li>\n<li>Graft-versus-host disease market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Graft-versus-host disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Graft-versus-host disease market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Got queries? Click here to know more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/graft-versus-host-disease-gvhd-market?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Graft-versus-host disease Market Landscape<\/a>.<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Graft-versus-host disease Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Graft-versus-host disease (GvHD) is an immune condition that occurs when immune cells (T cells) after transplant procedures from the donor (known as the graft or graft cells) attack the recipient patient host&rsquo;s tissues (healthy cells); the disease is a side effect that is common after an allogeneic bone marrow transplant (stem Cell Transplantation).<\/p>\n<p style=\"text-align: justify;\"><strong>Graft-versus-host disease Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Graft-versus-host disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as CSL Behring, Medac, ElsaLys Biotech, Kadmon Therapeutics, Incyte Corporation, and others during the forecasted period 2019-2032.<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more by requesting for sample <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-market?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Graft-versus-host disease Market Landscape&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Graft-versus-host disease Pipeline Therapies and Key Companies&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>CSL 964 AAT (Zemaira): CSL Behring<\/li>\n<li>Obnitix: Medac<\/li>\n<li>Leukotac (Inolimomab): ElsaLys Biotech<\/li>\n<li>KD025 (Belumosudil): Kadmon Therapeutics<\/li>\n<li>Itacitinib: Incyte Corporation<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Graft-versus-host disease Market Drivers&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increased participation in clinical trials along with novel strategies<\/li>\n<li>The rise in the number of cases of allogeneic stem cell transplant<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\">4. Graft-versus-host disease Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Graft-versus-host disease Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Graft-versus-host disease Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Graft-versus-host disease Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Graft-versus-host disease&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Graft-versus-host disease Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Graft-versus-host disease Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Graft-versus-host disease Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Graft-versus-host disease Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. Graft-versus-host disease Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Click here to read more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/graft-versus-host-disease-gvhd-market?utm_source=openpr&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Graft-versus-host disease Market Outlook 2032<\/a>.&nbsp;<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=graftversushost-disease-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-csl-behring-medac-elsalys-biotech-kadmon-therapeutics-incyte-cor\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=graftversushost-disease-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-csl-behring-medac-elsalys-biotech-kadmon-therapeutics-incyte-cor\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Graft-versus-host disease Market DelveInsight\u2019s \u2018Graft Versus Host Disease (GvHD) &#8211; Market Insights, Epidemiology, and Market Forecast\u20142032\u2019 report delivers an in-depth understanding of the GvHD, historical and forecasted epidemiology as well as the GvHD market trends in the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/graftversushost-disease-market-analysis-of-epidemiology-pipeline-products-and-key-companies-working-in-the-market-companies-csl-behring-medac-elsalys-biotech-kadmon-therapeutics-incyte-cor_648270.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-648270","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/648270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=648270"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/648270\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=648270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=648270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=648270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}